Growth Metrics

Resmed (RMD) Amortization of Deferred Charges (2019 - 2021)

Resmed's Amortization of Deferred Charges history spans 4 years, with the latest figure at $8.5 million for Q3 2021.

  • For Q3 2021, Amortization of Deferred Charges fell 18.28% year-over-year to $8.5 million; the TTM value through Sep 2021 reached $32.9 million, up 6.05%, while the annual FY2021 figure was $34.8 million, 31.06% up from the prior year.
  • Amortization of Deferred Charges reached $8.5 million in Q3 2021 per RMD's latest filing, down from $9.0 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $10.4 million in Q3 2020 to a low of $6.0 million in Q3 2019.
  • Average Amortization of Deferred Charges over 3 years is $7.8 million, with a median of $7.5 million recorded in 2020.
  • Peak YoY movement for Amortization of Deferred Charges: soared 74.78% in 2020, then dropped 18.28% in 2021.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $6.4 million in 2019, then grew by 17.75% to $7.5 million in 2020, then rose by 13.73% to $8.5 million in 2021.
  • Per Business Quant, the three most recent readings for RMD's Amortization of Deferred Charges are $8.5 million (Q3 2021), $9.0 million (Q2 2021), and $7.9 million (Q1 2021).